PROM1 and cancer: We further observed that LY294002 treatment reduced EMT by increasing the level of E-cadherin and decreasing the level of N-Cadherin, vimentin, and the markers of cancer stemness, where LY294 decreased the level of c-Kit, Oct4, CD133, and increased the level of CD24 in both cisplatin-sensitive and cisplatin-resistant versions of A2780 and MCW-OV-SL-3 cell lines (Figure 5D and Figure S2D).